4D Molecular Therapeutics (FDMT) Director Chacko Jacob Receives Award

What Happened Chacko Jacob, a director of 4D Molecular Therapeutics (FDMT), was granted 50,000 derivative shares (an award of stock options) on June 17, 2026. The filing reports the acquisition at $0.00 (no cash paid at grant). This is an award under the company’s non-employee director compensation program, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-17; filing date: 2026-06-18 (timely).
• Amount: 50,000 derivative shares (reported at $0.00).
• Shares owned after the transaction: not specified in the provided excerpt of the filing.
• Footnote F1: Award automatically granted under the non-employee director compensation program.
• Footnote F2: Options vest 1/3 on June 17, 2027, then monthly thereafter until fully vested on June 17, 2029; vesting accelerates upon a Change in Control.
• No indication of a 10b5-1 plan, gift, or tax withholding in the supplied notes.

Context This is a standard equity-based compensation grant for a non-employee director. As a derivative award (stock options), it does not represent immediate cash value — the eventual benefit depends on future vesting and the company’s stock price at exercise. The grant vests over three years (with full vesting on change-in-control), which aligns with typical director incentive arrangements.